HRSA has faced a major legal setback as a federal judge temporarily halts its 340B Rebate Model Pilot Program. A federal court has ordered a temporary halt to the federal government’s 340B Rebate Model Pilot Program, preventing it from taking effect on Jan. 1 as planned. The decision pauses a major operational change to how discounted outpatient drugs are provided to hospitals participating in the 340B program.
On Dec. 29, U.S. District Judge Lance Walker, chief judge of the U.S. District Court for the District of Maine, issued a preliminary injunction blocking the Health Resources and Services Administration (HRSA) from allowing the pilot to proceed. The judge found that the program was likely implemented in violation of the Administrative Procedure Act’s arbitrary and capricious standard.
The injunction prevents HRSA from permitting the nine participating drug manufacturers to replace the 340B program’s longstanding upfront drug discounts with a rebate-based model. Under the pilot, hospitals would have paid full drug prices initially and then sought rebates from manufacturers after drugs were dispensed.
In his order, Walker cited concerns about the agency’s administrative process and the lack of explanation regarding the program’s effects on 340B hospitals. “The Agency’s roll out has involved a rather threadbare administrative record that likely fails to consider and reasonably explain the impact of a rebate model on 340B hospitals, who rely on upfront price concessions to stretch few resources as far as possible to serve rural and poor communities,” Walker wrote.
The federal government had argued that any court-ordered pause should apply only to the hospital organizations that filed the lawsuit and their members. Walker rejected that position, writing that under the APA, the court has the authority to preliminarily set aside agency action on a broader basis.
The lawsuit was filed earlier in December by the American Hospital Association (AHA), the Maine Hospital Association, and four individual safety-net health systems. The plaintiffs argued that HRSA’s one-year test of the rebate model was hastily implemented and would impose substantial administrative and financial burdens on covered entities. They cited new reporting requirements and the need for hospitals to temporarily absorb drug costs while awaiting rebates.
According to the program design, covered entities would be required to submit a data report to drug manufacturers within 45 calendar days after a drug was dispensed, with allowances for extenuating circumstances. Manufacturers would then issue rebate payments within 10 days of receiving those reports.
The information technology systems used for reporting and rebate distribution would be overseen by the participating drugmakers, who would also have the ability to deny rebates for claims they determine to be duplicate or otherwise improper.
The plaintiffs also challenged the pace of the pilot’s rollout. They pointed to a July 31 proposal, a Sept. 8 public comment deadline, a Sept. 15 application deadline for manufacturers, and an Oct. 30 announcement approving participating companies. They argued that this timeline limited meaningful review and left hospitals with roughly two months to prepare for implementation.
The 340B program was created more than 30 years ago to provide discounted outpatient drugs to safety-net providers. Drug spending through the program has increased significantly over time, which manufacturers have cited as evidence that reforms are needed.
Participating drugmakers approved for the pilot include Bristol Myers Squibb, AstraZeneca, Merck Sharp Dohme, Novo Nordisk, Janssen Biotech, and others. Covered drugs include Eliquis, Enbrel, Farxiga, Jardiance, Stelara, and multiple insulin products, with Novartis’ Entresto approved for inclusion beginning April 1.
The court’s decision places immediate limits on HRSA’s ability to restructure the 340B program without a more detailed administrative record. For hospitals, the ruling preserves the existing upfront discount system that many rely on to manage drug costs and maintain services for underserved populations.
Legal observers note that the injunction could shape how HRSA approaches future pilot programs, particularly those involving payment reforms. Agencies may face increased pressure to demonstrate clearer justification, longer review periods, and more transparent assessments of financial impact before implementing changes.
For manufacturers, the pause delays a proposed shift they argued would improve oversight and curb misuse within the 340B system. The outcome of the case may ultimately influence broader policy debates around HRSA’s authority and the balance between cost containment and access to care.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
